Proton pump inhibitors have a short half-life and hence degrade quickly in the pH of the stomach. Therefore, developing a sustained release dosage form that can deliver a long-lasting and shield the medicine from the stomach's pH becomes crucial. Using organic solvents like ethanol and dichloromethane and polymers like Eudragit S100a and HPMC K15 in different ratios, the proton pump inhibitor microballoons were created by emulsion solvent evaporation. Following preparation, the microballoons were assessed for a number of parameters. For example, the micromeretics properties revealed that the tap density ranged from 0.803±0.36 to 0.923±0.06, the bulk density from 0.741±0.04 to 0.865±0.06, the Carr's index from 3.8±7.7 to 1.04±1.08 and the angle of repose from 14.860±0.47 to 20.250±0.71. The results of the buoyancy test indicated that the percentage was between 72.68±0.37 and 83.47±0.28, the percentage of drug entrapment was between 79.81±0.21 and 92.68±0.82, the yield percentage was between 79.20±0.28 and 89.38±0.25 and the cumulative drug release percentage was between 0.203 and 99.08%. Out of all the microballoon batches that were created, the P4 batch was determined to be the most optimal due to its optimal drug content percentage and drug release rate. The batch P4 was determined to be optimal since it exhibited the highest drug entrapment efficiency of 92.68±0.82%, the highest drug content of 94.72±0.006% and the highest sustained release action of 74.67% of drug release in a 12-hour period. The prepared microballoons were known to provide the necessary sustained release effect. The microballoons that were produced showed higuchi diffusion and zero order kinetics. It was determined to be stable since the stability analysis also revealed that there had been no appreciable alterations.
Loading....